New hope for kids with severe eczema: 2-Year dupilumab study shows promise

NCT ID NCT05983068

First seen Apr 19, 2026 · Last updated May 08, 2026 · Updated 5 times

Summary

This study looks at how well dupilumab (Dupixent) works over 2 years in children aged 6 to 14 with moderate-to-severe atopic dermatitis (eczema). About 48 kids will receive the drug and have their skin barrier function measured. The goal is to see if long-term treatment improves skin health and reduces water loss from the skin.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational Site Number : 8260001

    Sheffield, S10 2TH, United Kingdom

  • NYU Langone Medical Center- Site Number : 8400004

    New York, New York, 10016, United States

  • National Jewish Health Medical Center- Site Number : 8400001

    Denver, Colorado, 80206, United States

  • SSM Health Saint Louis University Hospital- Site Number : 8400006

    St Louis, Missouri, 63104, United States

Conditions

Explore the condition pages connected to this study.